People with obesity and diabetes may have an alternative way to get better with the psychedelic substance psilocybin.
Toronto-based biotechnology company Awakn has a research program on ketamine-assisted psychotherapy against multiple addictions.
Coryn Mayer says the healthcare system needs to improve if psilocybin therapy is to become a mainstream tool.
Vancouver biotechnology company Havn Life will export yield to UBC-based Delic Labs for quality control and testing.
The Vancouver-based company has a licence from Health Canada to test, sell, and distribute psychedelic substances.
Petter Grahl Johnstad of the University of Bergen says a bad psychedelics trip can be a way to confront personal demons.